Compounded GLP-1s made treatment affordable for millions of people, and the market that grew up around them is genuinely uneven. There have been product recalls, FDA inspection findings, warning letters to compounders and telehealth companies, and explicit alerts about counterfeit products carrying false label information. None of that means compounded medication is inherently unsafe. It means the variation between pharmacies is large and mostly invisible to patients — and there are specific questions that make it visible.
What the FDA has actually said and done
The regulatory record is a matter of public information, and it is worth knowing rather than guessing at.
- The FDA has stated it is aware of fraudulent compounded semaglutide and tirzepatide marketed in the US carrying false information on the product label.
- It has published adverse event reports received after patients used compounded semaglutide, and advises that patients should not use a compounded drug where an approved drug is available.
- In September 2025 the agency issued more than 55 warning letters to online sellers of compounded GLP-1 products.
- During June 2026 it issued a further 25 warning letters to telehealth companies over alleged false or misleading promotional claims, with reporting describing 30 letters in total across that action.
- It has cited telehealth marketing that falsely suggests compounded GLP-1s are identical to approved products, and that misrepresents sourcing.
The claim regulators keep targeting
The specific marketing the FDA has repeatedly acted against is the suggestion that a compounded product is the same as an FDA-approved one. It is not. The molecule is intended to be the same; the manufacturing process, quality control, testing regime, and regulatory review are not. Any platform telling you otherwise is making exactly the claim regulators have been issuing letters about.
Specific incidents worth knowing
Two named cases illustrate the range of what has gone wrong, and both involved pharmacies whose products reached patients through telehealth platforms.
- 1
A Class II recall of compounded semaglutide
ProRx initiated a voluntary recall of semaglutide injections in October 2025, with affected products distributed across Texas and Utah. In May 2026 the FDA issued the same facility a warning letter citing its production of tirzepatide, which it stated was not eligible for compounding.
- 2
An inspection finding and product recall
GenoGenix received an FDA Form 483 following inspection in July 2025, with its recalled product scope including 10 mL vials of tirzepatide. The company subsequently published material describing quality improvements made after the audit.
- 3
Voluntary nationwide recalls
The FDA's compounding inspections and recalls page records further 483 findings and voluntary nationwide recall actions across the sector during 2026.
The pattern is not that compounding is unsafe. It is that oversight of compounded products is inspection-driven and reactive, so problems surface after products have already reached patients rather than before.
Why patients cannot see any of this
The central practical problem is that most telehealth platforms will not tell you which pharmacy compounds your medication. Without that name, none of the public record above is usable — you cannot look up inspection findings, recalls, or warning letters for a facility you cannot identify.
This is not a minor inconvenience. It is the single most consequential information asymmetry in the compounded GLP-1 market, and it exists because opacity is commercially convenient rather than because the information is unavailable.
A small number of platforms do disclose. Some name their partner pharmacies openly, and at least one lets patients choose between named facilities. Those platforms are behaving materially better than the rest, and it is a reasonable factor in choosing between them.
How to vet a compounding pharmacy
- Ask which pharmacy compounds your medication, by name. Treat refusal as an answer.
- Ask whether it is a 503A pharmacy or a 503B outsourcing facility. 503B facilities are registered with the FDA and subject to different, generally more rigorous, manufacturing standards.
- Ask whether sterility and endotoxin testing is performed on every batch, and whether results are available. These are the two tests that matter most for a sterile injectable.
- Search the FDA's compounding inspections and recalls page for the named facility before your first order.
- Be sceptical of combination products adding B12, glycine, or L-carnitine. The evidence for the additions is weak and they complicate what you are actually receiving.
- Check the labelling on arrival. The FDA has specifically warned about products carrying false label information.
The regulatory position on availability
The FDA's guidance is that patients should not use a compounded drug where an approved drug is available. Since manufacturer direct-pay channels now sell FDA-approved GLP-1s at a few hundred dollars a month, the gap between compounded and approved options is narrower than it was — which changes the calculation for many patients.
How to weigh the risk honestly
Two things are true at once, and most coverage of this subject picks one and ignores the other.
The first is that compounded GLP-1s have made treatment accessible to millions of people who could not otherwise afford it, and the overwhelming majority of patients using them report normal outcomes. Treating the entire category as dangerous is not supported by the evidence and would push people back toward no treatment at all.
The second is that quality varies enormously between facilities, oversight is reactive, and patients typically cannot see which pharmacy they are dealing with. That is a real problem and it is not solved by reassurance.
The reasonable position is to use compounded medication where cost requires it, insist on knowing the pharmacy, prefer platforms that disclose testing, and price manufacturer direct-pay alternatives before assuming compounded is the only affordable route.
Key Takeaways
- →The FDA has issued recalls, 483 findings, and dozens of warning letters across the compounded GLP-1 sector.
- →It has specifically warned about fraudulent products carrying false label information.
- →Regulators have repeatedly acted against marketing claiming compounded products are identical to approved ones.
- →Quality varies between facilities rather than being inherent to compounding.
- →Most platforms will not name their pharmacy, which makes the public safety record unusable to patients.
- →Manufacturer direct-pay pricing has narrowed the gap, changing the calculation for many people.
Frequently Asked Questions
Are compounded GLP-1s dangerous?+
Not inherently, and the overwhelming majority of patients report normal outcomes. But quality varies substantially between facilities, oversight is reactive rather than preventive, and the FDA has issued recalls, inspection findings, and warnings about fraudulent products with false labelling. The risk is variation you cannot see.
What has the FDA actually done?+
It has issued more than 55 warning letters to online sellers of compounded GLP-1s in September 2025, a further 25 to telehealth companies in June 2026 over misleading claims, warning letters to specific compounders, and alerts about fraudulent products with false label information. It also publishes compounding inspection and recall records.
What is the difference between a 503A and 503B pharmacy?+
503A pharmacies compound for individual patients under state pharmacy board oversight. 503B outsourcing facilities are registered with the FDA and subject to different, generally more rigorous manufacturing standards. Knowing which you are dealing with is a meaningful piece of information.
Why won't my platform tell me which pharmacy it uses?+
Because opacity is commercially convenient rather than because the information is unavailable. A small number of platforms do disclose their partner pharmacies openly, and at least one lets patients choose between named facilities. Treat refusal to answer as an answer.
What should I ask before my first order?+
Which pharmacy compounds the medication by name, whether it is 503A or 503B, and whether sterility and endotoxin testing is performed on every batch. Then search the FDA's compounding inspections and recalls page for that facility before ordering.
Should I switch to brand-name medication?+
The FDA's guidance is that patients should not use a compounded drug where an approved drug is available, and manufacturer direct-pay channels now sell FDA-approved GLP-1s at a few hundred dollars a month. Run the arithmetic on your own situation — the gap is narrower than most people assume.
Looking for a provider?
We have reviewed 167 GLP-1 providers and ranked them by category:
Related Reading
This article is educational content, not medical advice. GLP-1 medications require a prescription and clinical supervision — talk to a licensed clinician about whether treatment is appropriate for you. See our medical disclaimer.